European retrospective study of real-life haemophilia treatment

Haemophilia

Volumn 23, Issue 1, 2017, Pages 105-114

  Berntorp, E ^a   Dolan, G ^b   Hay, C ^c   Linari, S ^d   Santagostino, E ^e   Tosetto, A ^f   Castaman, G ^d,f   Alvarez Roman M T ^g   Parra Lopez, R ^h   Oldenburg, J ⁱ   Albert, T ⁱ   Scholz, U ^j   Holmstrom M ^k,l   Schved, J F ^m   Trossaert M ⁿ   Hermans, C ^o   Boban, A ^o,p   Ludlam, C ^q,r   Lethagen, S ^q,s  

^a LUND UNIVERSITY   (Sweden)

^b ST THOMAS HOSPITAL   (United Kingdom)

^c MANCHESTER ROYAL INFIRMARY   (United Kingdom)

^d CAREGGI UNIVERSITY HOSPITAL   (Italy)

^e FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

^f SAN BORTOLO HOSPITAL   (Italy)

^g HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^h HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

ⁱ UNIVERSITY HOSPITAL BONN   (Germany)

^j MVZ Labor Leipzig   (Germany)

^k KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^l KAROLINSKA INSTITUTE   (Sweden)

^m HÔPITAL SAINT ELOI   (France)

ⁿ NANTES UNIVERSITY HOSPITAL   (France)

^o CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

^p UNIVERSITY OF ZAGREB   (Croatia)

^q SOBI   (Sweden)

^r UNIVERSITY OF EDINBURGH   (United Kingdom)

^s UNIVERSITY OF COPENHAGEN   (Denmark)

more..

Author keywords

factor IX; factor VIII; haemophilia A; haemophilia B; retrospective study; treatment

Indexed keywords

BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 9;

ADOLESCENT; ADULT; ANNUAL BLEEDING RATE; ARTICLE; BLEEDING; CHILD; DISEASE SEVERITY; EUROPE; GEOGRAPHIC DISTRIBUTION; HEMATOLOGICAL PARAMETERS; HEMOPHILIA A; HEMOPHILIA B; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROPHYLAXIS; RETROSPECTIVE STUDY; TREATMENT DURATION; CLINICAL TRIAL; MULTICENTER STUDY;

ADULT; EUROPE; HEMOPHILIA A; HUMANS; MALE; RETROSPECTIVE STUDIES;

EID: 84992471334     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/hae.13111     Document Type: Article

References (16)

1. Srivastava A, Brewer AK, Mauser-Bunschoten EP et al. Guidelines for the management of hemophilia. Haemophilia 2013; 19: e1–47.
2. den Uijl I, Biesma D, Grobbee D, Fischer K. Outcome in moderate haemophilia. Blood Transfus 2014; 12(Suppl 1): s330–6.
3. Fischer K, Steen Carlsson K, Petrini P et al. Intermediate-dose versus high-dose prophylaxis for severe hemophilia: comparing outcome and costs since the 1970s. Blood 2013; 122: 1129–36.
4. Tang L, Wu R, Sun J et al. Short-term low-dose secondary prophylaxis for severe/moderate haemophilia A children is beneficial to reduce bleed and improve daily activity, but there are obstacle in its execution: a multi-centre pilot study in China. Haemophilia 2013; 19: 27–34.
5. Gringeri A, Lundin B, von Mackensen S, Mantovani L, Mannucci PM, ESPRIT Group. A randomized clinical trial of prophylaxis in children with hemophilia A (the ESPRIT Study). J Thromb Haemost 2011; 9: 700–10.
6. Manco-Johnson MJ, Abshire TC, Shapiro AD et al. Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. N Engl J Med 2007; 357: 535–44.
7. Oldenburg J. Optimal treatment strategies for hemophilia: achievements and limitations of current prophylactic regimens. Blood 2015; 125: 2038–44.
8. O'Mahony B, Noone D, Giangrande PL, Prihodova L. Haemophilia care in Europe – a survey of 35 countries. Haemophilia 2013; 19: e239–47.
9. U.K.H.C.D. Organisation. Available at http://www.ukhcdo.org/. Accessed October 12, 2016.
10. Lindvall K, Swedenborg N. UMAS hemophilia database. Stud Health Technol Inform 2006; 122: 853.
11. Blanchette VS, Key NS, Ljung LR et al. Definitions in hemophilia: communication from the SSC of the ISTH. J Thromb Haemost 2014; 12: 1935–9.
12. Marshall MA, Mazepa PE, Baker JR, Riske BK, Soucie JM. Men with severe hemophilia in the United States: birth cohort analysis of a large national database. Blood 2016; 127: 3073–81.
13. van den Berg HM, Fischer K, van der Bom JG. Comparing outcomes of different treatment regimens for severe haemophilia. Haemophilia 2003; 9(Suppl 1): 27–31.
14. Mannucci PM, Franchini M. Is haemophilia B less severe than haemophilia A? Haemophilia 2013; 19: 499–502.
15. Collins PW, Fischer K, Morfini M, Blanchette VS, Bjorkman S, International Prophylaxis Study Group Pharmacokinetics Expert Working Group. Implications of coagulation factor VIII and IX pharmacokinetics in the prophylactic treatment of haemophilia. Haemophilia 2011; 17: 2–10.
16. Ceponis A, Wong-Sefidan I, Glass CS, von Drygalski A. Rapid musculoskeletal ultrasound for painful episodes in adult haemophilia patients. Haemophilia 2013; 19: 790–8.